Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PREDIX II HER2: Atezolizumab in HER2-positive Breast Cancer
NCT03894007Phase 2Terminated
- Start
- May 2019
- Primary completion
- Jun 2021
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of atezolizumab in HER2-positive breast cancer. Started May 2019; status: terminated.
02
Drugs
atezolizumab
03
Conditions
HER2-positive breast cancer
Beyond the preview
Go deeper on NCT03894007.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03894007.